Resonance Health Ltd (ASX: RHT) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Resonance Health Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $80.65 million
P/E Ratio 135.14
Dividend Yield N/A
Shares Outstanding 461.15 million
Earnings per share 0.001
Dividend per share N/A
Year To Date Return 25.00%
Earnings Yield 0.74%
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Resonance Health Ltd (ASX: RHT)
Latest News

RHT ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Resonance Health Ltd

Resonance Health Ltd is a healthcare company specializing in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality controlled environment. Its product includes FerriScan, a non-invasive liver diagnostic technology used for the measurement of iron in the liver and HepaFat-Scan. The company's operating segment includes Services; Research and Development and Corporate. It generates maximum revenue from the Services segment. Geographically, it derives a majority of revenue North America and Europe-Middle-East-Africa (EMEA) and also has a presence in Asia/Pacific.

RHT Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
21 Jan 2022 $0.18 $0.00 0.00% 212,115 $0.18 $0.18 $0.18
20 Jan 2022 $0.18 $-0.02 -10.53% 113,552 $0.19 $0.19 $0.18
19 Jan 2022 $0.19 $0.00 0.00% 85,063 $0.18 $0.19 $0.18
18 Jan 2022 $0.19 $-0.01 -5.13% 20,811 $0.19 $0.19 $0.19
17 Jan 2022 $0.20 $0.01 5.41% 1,496,954 $0.19 $0.20 $0.18
14 Jan 2022 $0.19 $-0.01 -5.13% 385,700 $0.19 $0.19 $0.19
13 Jan 2022 $0.20 $-0.01 -5.00% 607,297 $0.20 $0.20 $0.18
12 Jan 2022 $0.20 $0.04 24.24% 1,424,266 $0.17 $0.20 $0.17
11 Jan 2022 $0.17 $-0.01 -5.88% 119,133 $0.18 $0.18 $0.17
10 Jan 2022 $0.17 $0.01 6.06% 702,215 $0.17 $0.18 $0.17
07 Jan 2022 $0.17 $0.00 0.00% 41,970 $0.17 $0.17 $0.17
06 Jan 2022 $0.17 $-0.01 -5.71% 563,859 $0.17 $0.17 $0.17
05 Jan 2022 $0.18 $0.03 20.00% 3,559,670 $0.16 $0.18 $0.16
04 Jan 2022 $0.15 $0.01 7.14% 708,053 $0.15 $0.16 $0.15
31 Dec 2021 $0.14 $0.00 0.00% 786,823 $0.15 $0.15 $0.14
30 Dec 2021 $0.15 $0.04 36.36% 8,103,626 $0.15 $0.17 $0.14
29 Dec 2021 $0.11 $0.01 10.00% 4,590 $0.11 $0.11 $0.11

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
30 Jun 2021 Travis Baroni Buy 132 $21,200
On-market trade.
23 Jun 2021 Simon Panton Buy 300 $45,000
As advised by the company. Market purchase
09 Mar 2021 Travis Baroni Transfer 282 $52,262
Off-market transfer.
09 Mar 2021 Travis Baroni Sell 1 $222,000
As advised by the company. 1.2 million unlisted options at various exercise prices. Shares and unlisted options are now held in a new entity that Dr Travis Baroni has no involvement with.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Martin Peter Blake Non-Executive DirectorNon-Executive Chairman Oct 2007
Dr Blake brings technical and industry experience to Resonance Health. He has been a Partner of Perth Radiological Clinic since 1997 and is currently the Chairman of that Company. He is Member of Risk Committee.
Mr Mitchell MacDonald Wells Executive DirectorManaging Director Feb 2018
Mr Wells has worked as a senior executive and as a Director of several ASX and US Nasdaq listed public companies. He has international project management and legal experience, having worked as a project manager and as a corporate and contracts consultant in Australia, the USA, and the United Kingdom. Mr Wells' career started as a lawyer working in law firms before transitioning to an executive role in the UK as a founding executive of London's bid to host the 2012 Olympic & Paralympic Games. He then worked as a project manager on the redevelopment of The O2 Arena precinct in London, regarded by many as Europe's entertainment precinct. Mitchell returned to Australia in 2008 to take up the role of COO, and ultimately CEO, of ASX listed Amadeus Energy Ltd, which was acquired by US based Lonestar Resources Inc. He then facilitated Lonestar's listing on the US Nasdaq and went on to serve as a Director of the Nasdaq listed parent and as Australia country representative. Mr Wells is also a commercial (aircraft) pilot and has served as Chair of two sizable not-for-profit organizations, including Guildford Grammar School.
Mr Simon Panton Non-Executive Director Oct 2009
Mr Panton has been supporter of FerriScan technology over a number of years and is shareholder of Resonance Health. Mr Panton brings skills in business and marketing having run his own business. He is Member of Risk Committee.
Dr Travis Baroni Non-Executive Director Nov 2016
Mr Baroni has experience across industrial research, commercialisation of technology, asset valuations and investment banking services. He has managed innovation development and technology strategy in a company setting as well as being an investor in early stage investments. He has worked in investment banking, providing advisory services to equity capital market transactions, corporate research and valuations to clients. He is Chairman of Risk Committee.
Mr Nicholas (Nick) Allan Chief Financial OfficerCompany Secretary May 2021
-
Nicholas (Nick) Allan Chief Financial OfficerCompany Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Southam Investments 2003 Pty Ltd (Warwickshire Investment A/C) 73,300,000 15.90%
HSBC Custody Nominees (Australia) Limited 43,293,525 9.39%
Acuity Capital Investment Management Pty Ltd (Acuity Capital Holdings A/C) 20,000,000 4.34%
Ms Alison Virginia Wesley (Wesley Family A/C) 10,000,000 2.17%
Mr Paul John Van Dyk 9,349,700 2.03%
Mr William Murray Thompson 6,658,660 1.44%
Ms Jade Louise Thompson 6,512,759 1.41%
Mr Bruce Alan Stevenson 6,300,000 1.37%
Mr Helmut Rocker 6,250,000 1.36%
Marcolongo Nominees Pty Ltd (Marcolongo Family A/C) 5,186,200 1.12%
The Majobri Holdings Pty Ltd (The Majobri Family A/C) 4,500,000 0.98%
Mr Thomas Psarakis 4,434,777 0.96%
Mr Harish Garg 4,001,245 0.87%
BNP Paribas Nominees Pty Ltd (IB AU Noms Retailclient DRP) 3,890,663 0.84%
Dr Martin Peter Blake 3,798,590 0.82%
Mr Vincent Oladele 3,708,052 0.80%
Morgan Stanley Australia Securities (Nominee) Pty Limited (No 1 Account) 3,588,012 0.78%
Fullerton Private Capital Pty Limited 3,500,000 0.76%
The University Of Western Australia 3,478,750 0.75%
Neweconomy Com Au Nominees Pty Limited (900 Account) 3,389,575 0.74%

Profile

since

Note